AR101510A1 - Agentes anti-trichophyton cristalinos y proceso de preparación de los mismos - Google Patents

Agentes anti-trichophyton cristalinos y proceso de preparación de los mismos

Info

Publication number
AR101510A1
AR101510A1 ARP150102603A ARP150102603A AR101510A1 AR 101510 A1 AR101510 A1 AR 101510A1 AR P150102603 A ARP150102603 A AR P150102603A AR P150102603 A ARP150102603 A AR P150102603A AR 101510 A1 AR101510 A1 AR 101510A1
Authority
AR
Argentina
Prior art keywords
preparation process
cristalinos
trichophyton
agents
same preparation
Prior art date
Application number
ARP150102603A
Other languages
English (en)
Inventor
Watanabe Takashi
Ohyama Makoto
Mori Kenichiro
Imai Takahiro
Sasaki Toshiro
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of AR101510A1 publication Critical patent/AR101510A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente solicitud proporciona una forma de cristal de 2-(3,5-dimetil-1H-pirazol-1-il)-5-metilfenol que es estable y de alta pureza para la preservación, manufactura industrial, y circulación, y su proceso de preparación, y en forma específica, la presente solicitud proporciona, mediante el uso de un compuesto de boro, cristales estables y de alta pureza de 2-(3,5-dimetil-1H-pirazol-1-il)-5-metilfenol y el proceso de preparación. Reivindicación 1: Cristales de un compuesto caracterizado porque está representado por la fórmula (1).
ARP150102603A 2014-08-13 2015-08-12 Agentes anti-trichophyton cristalinos y proceso de preparación de los mismos AR101510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014165038 2014-08-13

Publications (1)

Publication Number Publication Date
AR101510A1 true AR101510A1 (es) 2016-12-21

Family

ID=55304229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102603A AR101510A1 (es) 2014-08-13 2015-08-12 Agentes anti-trichophyton cristalinos y proceso de preparación de los mismos

Country Status (11)

Country Link
US (1) US10562858B2 (es)
EP (1) EP3190105A4 (es)
JP (2) JP6576930B2 (es)
KR (1) KR102137861B1 (es)
CN (2) CN110218187A (es)
AR (1) AR101510A1 (es)
AU (1) AU2015302633B2 (es)
CA (1) CA2957880A1 (es)
RU (1) RU2017107455A (es)
TW (1) TW201613870A (es)
WO (1) WO2016024602A1 (es)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475944A (en) 1982-06-09 1984-10-09 E. I. Du Pont De Nemours And Company Herbicidal sulfamates
DE3628892A1 (de) 1986-08-26 1988-03-10 Bayer Ag Substituierte 1-aryl-3-tert.-butyl-pyrazole
ES2015648A6 (es) 1989-05-05 1990-09-01 Consejo Superior Investigacion Procedeimiento de sintesis de mono y bis (3-r3-4-r4-5-r5-pirazol-1-il)1,4-dihidroxibencenos.
US5391367A (en) 1993-07-28 1995-02-21 Pfizer Inc. Antifungal nail solution
CA2277990C (en) * 1997-02-10 2006-08-01 Pfizer Products Inc. 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
US6727401B1 (en) 1998-02-12 2004-04-27 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
CA2453147A1 (en) 2001-07-11 2003-01-23 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
JP2003344278A (ja) 2002-05-28 2003-12-03 Shiseido Co Ltd つめ水分の測定方法
JP4537855B2 (ja) 2002-10-09 2010-09-08 久光製薬株式会社 抗真菌活性を有する新規ピラゾール化合物
KR100509603B1 (ko) 2002-12-28 2005-08-22 삼성에스디아이 주식회사 적색 발광 화합물 및 이를 채용한 유기 전계 발광 소자
JP4540667B2 (ja) 2003-03-21 2010-09-08 ネクスメツド・ホールデイングス・インコーポレイテツド 抗真菌性ネイルコート
JP4507163B2 (ja) 2003-10-17 2010-07-21 道正 秦名 フィルム状の美爪化粧料及び化粧方法並びにその化粧具
JP4873871B2 (ja) 2005-02-28 2012-02-08 久光製薬株式会社 粘着剤及び貼付剤
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
EP2057988B1 (en) 2006-08-28 2013-09-11 Hisamitsu Pharmaceutical Co., Inc. Nail patch
JP2008169155A (ja) 2007-01-12 2008-07-24 Sato Pharmaceutical Co Ltd 爪に対する薬物の浸透促進剤及びそれを含有する外用爪治療剤
WO2009041121A1 (ja) 2007-09-28 2009-04-02 Yugen Kaisha Kazki Reiko 化粧補助貼付材及び該貼付材を用いた化粧方法
JP2011503222A (ja) 2007-11-20 2011-01-27 ガルデルマ・ソシエテ・アノニム イオン導入による爪疾患の処置のためのアモロルフィンの使用
EP2518054A1 (en) * 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
RU2593990C2 (ru) * 2011-01-30 2016-08-10 Мейдзи Сейка Фарма Ко., Лтд. Местное противогрибковое средство
JP6132842B2 (ja) 2012-07-30 2017-05-24 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 抗白癬菌症外用液剤
US20150209301A1 (en) * 2012-07-30 2015-07-30 Nichiban Company Limited Patch for anti-dermatophytosis

Also Published As

Publication number Publication date
AU2015302633B2 (en) 2020-01-16
US20170233346A1 (en) 2017-08-17
EP3190105A4 (en) 2018-05-30
RU2017107455A3 (es) 2019-02-27
KR102137861B1 (ko) 2020-07-24
TW201613870A (en) 2016-04-16
EP3190105A1 (en) 2017-07-12
CA2957880A1 (en) 2016-02-18
RU2017107455A (ru) 2018-09-13
CN106573892B (zh) 2019-10-25
JP2020007328A (ja) 2020-01-16
US10562858B2 (en) 2020-02-18
CN110218187A (zh) 2019-09-10
JP6576930B2 (ja) 2019-09-18
KR20170042642A (ko) 2017-04-19
WO2016024602A1 (ja) 2016-02-18
AU2015302633A1 (en) 2017-03-02
CN106573892A (zh) 2017-04-19
JPWO2016024602A1 (ja) 2017-05-25

Similar Documents

Publication Publication Date Title
CU20170087A7 (es) Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
CR20150629A (es) Compuestos químicos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
SV2015005074A (es) Formas cristalinas de inhibidores de tirosina cinasa y sus sales
CL2017000293A1 (es) Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)
CL2017002694A1 (es) Métodos para mejora hidráulica de cultivos
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
CR20180328A (es) Compuestos de isoindol
AR102790A1 (es) Composiciones antimicrobianas y métodos relacionados para tratar productos alimenticios y superficies
AR095727A1 (es) Preparación de intermediarios de pirimidina
CR20160016A (es) Pirazolpiridinas sustituidas
DOP2016000242A (es) Uso de compuestos heterocíclicos para controlar nematodos
CL2015001289A1 (es) Nuevos derivados de 1,4-ditiina sustituida y su uso como fungicidas
AR098592A1 (es) Formas cristalinas de 1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azulenos
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
AR101510A1 (es) Agentes anti-trichophyton cristalinos y proceso de preparación de los mismos
AR102569A1 (es) Síntesis de inhibidor de pi3k, formas cristalinas y sales del mismo y una composición farmacéutica que lo comprende

Legal Events

Date Code Title Description
FB Suspension of granting procedure